US equities |
TSLA $391.62 ▲+5.21% MU $903.70 ▲+2.98% META $630.56 ▼-1.88% NVDA $216.00 ▲+2.39% AAPL $343.91 ▼-1.10% SPCX $146.90 ▼-0.40% MSFT $532.60 ▲+1.54% AMD $531.28 ▲+2.80%
FinancialContent

Articles published by BONE BIOLOGICS CORPORATION

News headline image
Bone Biologics Expands Trial Sites
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
Tickers BBLG BBLGW
News headline image
Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
Tickers BBLG BBLGW
News headline image
Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
Tickers BBLG BBLGW
News headline image
Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
Tickers BBLG BBLGW
News headline image
Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
Tickers BBLG BBLGW
News headline image
Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
Tickers BBLG BBLGW
News headline image
Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
Tickers BBLG BBLGW
News headline image
Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
Tickers BBLG BBLGW
News headline image
Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG BBLGW
News headline image
Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG BBLGW
News headline image
Bone Biologics Announces Closing of $5.0 Million Public Offering
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG BBLGW
News headline image
Bone Biologics Announces Pricing of $5.0 Million Public Offering
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG BBLGW
News headline image
Bone Biologics Files Patent Application for Bone Regeneration Technology
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG BBLGW
News headline image
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG BBLGW
News headline image
Bone Biologics Announces 1-for-6 Reverse Stock Split
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG BBLGW
News headline image
Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
News headline image
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG BBLGW
News headline image
First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG BBLGW
News headline image
Bone Biologics Announces Closing of $2.0 Million Public Offering
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
News headline image
Bone Biologics Announces Pricing of $2.0 Million Public Offering
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
News headline image
Bone Biologics Reports Progress With NB1 Clinical Program
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
News headline image
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG BBLGW
News headline image
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG BBLGW
News headline image
Bone Biologics Announces 1-for-8 Reverse Stock Split
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG BBLGW
News headline image
Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
News headline image
Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
News headline image
Bone Biologics Prices $5.0 Million Underwritten Public Offering
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
News headline image
Bone Biologics Effects 1-for-30 Reverse Stock Split
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
News headline image
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
News headline image
Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG